U.S. markets closed
  • S&P Futures

    4,336.50
    -6.75 (-0.16%)
     
  • Dow Futures

    33,769.00
    -29.00 (-0.09%)
     
  • Nasdaq Futures

    14,986.50
    -37.50 (-0.25%)
     
  • Russell 2000 Futures

    2,177.60
    -3.30 (-0.15%)
     
  • Crude Oil

    70.51
    -0.05 (-0.07%)
     
  • Gold

    1,776.10
    -2.10 (-0.12%)
     
  • Silver

    22.77
    +0.16 (+0.70%)
     
  • EUR/USD

    1.1733
    +0.0003 (+0.02%)
     
  • 10-Yr Bond

    1.3240
    +0.0150 (+1.15%)
     
  • Vix

    24.36
    -1.35 (-5.25%)
     
  • GBP/USD

    1.3671
    +0.0007 (+0.05%)
     
  • USD/JPY

    109.3870
    +0.1670 (+0.15%)
     
  • BTC-USD

    41,876.00
    +128.22 (+0.31%)
     
  • CMC Crypto 200

    1,034.63
    -29.21 (-2.75%)
     
  • FTSE 100

    6,980.98
    +77.07 (+1.12%)
     
  • Nikkei 225

    29,607.52
    -232.19 (-0.78%)
     

Infinity Pharma Stock Drops After Updated Data From Bladder & Breast Cancer Trials, Q2 Earnings

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Infinity Pharmaceuticals Inc (NASDAQ: INFI) has issued data updates from two mid-stage trials for eganelisib, its oral immuno-oncology candidate.

Data: 49 patients were enrolled in the MARIO-275 study designed to evaluate it as a combination therapy with Bristol-Myers Squibb Co's (NYSE: BMY) Opdivo (nivolumab) in platinum-refractory, I/O naïve patients with advanced urothelial cancer.

In the combination arm, the median overall survival (mOS) in the intent to treat (ITT) population stood at 15.4 months versus 7.9 months on the control arm of nivolumab alone, reflecting a 38% lower probability of death on the combination arm.

At year one, 59% of patients in the ITT population receiving the combo were alive compared to 32% in the control arm. mOS benefit was similar across those with PD-L1(-) tumors and in the ITT population, while most common treatment-emergent adverse events (TEAEs) included pyrexia (33.3%) and decreased appetite (30.3%).

There were no Grade 5 hepatic AEs, the Company said. Meanwhile, the MARIO-3 was designed to evaluate eganelisib in a front-line setting as a triple combination with Roche Holding AG's (OTC: RHHBY) Tecentriq (atezolizumab) and Bristol-Myers's Abraxane (nab-paclitaxel) in patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC).

Out of 43 patients enrolled and 38 evaluable, 86.8% (33/38) of evaluable patients demonstrated tumor reduction while disease control rate (DCR) stood at 84.2% (32/38) for all patients.

View more earnings on RHHBF

DCR reached 91.7% (11/12) and 78.2% (18/23) for those with PD-L1 negative and positive tumors, respectively. The most common TEAEs included nausea (51.2%) and fatigue (48.8%) with no Grade 5 hepatic AEs.

One patient had permanently discontinued the study due to an elevated liver function test.

Q2 Earnings: Concurrently, the Company released Q2 2021 financials and estimated its FY2021 net loss to be $40M – $50M indicating around +11.1% Y/Y.

The cash balance stood at $97.3 million to fund eganelisib development.

Price Action: INFI shares are down 29.5% at $1.57 during the market session on the last check Tuesday.

Photo by marijana1 from Pixabay

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.